معرفی
Donata Vercelli, MD is a Professor in the Department of Cellular and Molecular Medicine at the University of Arizona and a Professor at the BIO5 Institute. She serves as Director of the Molecular Genomics core at the Arizona Arthritis Center (A2DRC) and Director of the Arizona Center for the Biology of Complex Diseases. Her research investigates genetic, epigenetic, and environmental mechanisms controlling susceptibility to complex lung diseases.
Her research spans Genetics, Epigenetics, Environmental Health, Lung Diseases, Asthma, Allergic Diseases, Microbiota, and Immunology. She examines how maternal immunity, neonatal trained immunity, and early airway microbiota shape childhood asthma development. Recent work explores bacterial lysates like OM-85 for blocking experimental asthma and inhibiting SARS-CoV-2 infection through modulation of immune pathways.
Analysis of her 2017-2022 publications reveals dominant themes in microbiota-epigenetics-immunity interactions in asthma pathogenesis. Key trends include airway microbiome impacts during infancy, trained immunity mechanisms, type 2 inflammation modulation of viral receptors, and cross-border epidemiological studies on asthma prevalence. Her work integrates genomic, immunological, and clinical approaches across diverse cohorts.
Dr. Vercelli serves as Principal Investigator for active clinical trials including BEAMS (studying environmental exposures and asthma in Arizona-Sonora border children) and OM-Pharma (evaluating bacterial lysate for asthma prevention). Her leadership in these trials demonstrates active grant funding and translational research impact despite no specific grant details provided.
She directs the Molecular Genomics core at A2DRC and the Arizona Center for the Biology of Complex Diseases, establishing interdisciplinary infrastructure for genomic analysis of complex disease mechanisms. These centers facilitate collaborative research on asthma pathogenesis through molecular profiling and systems biology approaches.
